Educational only — not medical advice. If you’re in crisis or thinking about suicide: call or text 988 (U.S.) or your local emergency number. Support resources. Under construction and review—see the updates log.

desvenlafaxine

Adjunctive therapy

Brand: Pristiq

Published 2026-03-24 · Last reviewed 2026-03-31 · 4 references

Content sourced from FDA labeling (DailyMed) and peer-reviewed literature.

Print sheet Review evidence

At a glance

Class: Adjunctive therapy·Typical dose: Label dose is 50 mg once daily with or without food; doses >100 mg/day add little efficacy and increase adverse effects.·Half-life: Single-dose mean 11 h; Single-dose range 9–13 h; Steady-state mean 11 h·LAI available: No

Class: Adjunctive therapy
Typical dose: Label dose is 50 mg once daily with or without food; doses >100 mg/day add little efficacy and increase adverse effects.
Half-life: Single-dose mean 11 h; Single-dose range 9–13 h; Steady-state mean 11 h
LAI available: No

Quick answers

What is desvenlafaxine?: Desvenlafaxine (brand Pristiq) is the primary active metabolite of venlafaxine and an SNRI approved for major depressive disorder.
What is Pristiq?: Pristiq is a brand name for desvenlafaxine.
What is Pristiq (desvenlafaxine) used for?: Label indications include: Major depressive disorder.
What drug class is Pristiq (desvenlafaxine)?: SNRI Antidepressant.
What is the mechanism of action of Pristiq (desvenlafaxine)?: Serotonin-norepinephrine reuptake inhibitor (SNRI); active metabolite of venlafaxine.
What strengths does Pristiq (desvenlafaxine) come in?: Extended-release tablets: 25 mg, 50 mg, 100 mg.

General information

Desvenlafaxine (brand Pristiq) is the primary active metabolite of venlafaxine and an SNRI approved for major depressive disorder.

Because activation does not require CYP2D6, exposure is more predictable across metabolizer phenotypes and drug–drug interaction profiles than venlafaxine.

The compare view, desvenlafaxine evidence feed, and bipolar disorder hub can be used together when aligning taper strategies, monitoring blood pressure effects, and accounting for bipolar-spectrum risk.

Discontinuation symptoms can still occur despite once-daily dosing; predictable taper plans can reduce withdrawal, especially after long-term use.

U.S. approvals

Major depressive disorder (adults) (2008)

Formulations & strengths

Extended-release tablets: 25 mg, 50 mg, 100 mg.

Generic availability

Generic extended-release tablets available since 2017.

Clinicians often choose desvenlafaxine after SSRI nonresponse or when venlafaxine’s CYP2D6 interactions are problematic. Blood pressure monitoring and taper planning are key considerations due to dose-related hypertension and withdrawal symptoms. In bipolar-spectrum illness, mood stabiliser coverage is typically maintained, and coordination with the bipolar disorder hub can help clarify relapse-prevention plans.

View labelExact

Mechanism of action

Refer to the Glossary entry on Neurotransmitters for background on receptor systems involved in serious mental illness.

Inhibits serotonin (SERT) and norepinephrine (NET) transporters, increasing synaptic concentrations of both neurotransmitters.

Minimal affinity for dopaminergic, histaminergic, or muscarinic receptors; norepinephrine contribution plateaus near 100 mg/day.

SERT and NET inhibition with minimal direct receptor antagonism.

Metabolism & pharmacokinetics

Oral bioavailability ≈80%; peak plasma concentrations occur ~7.5 hours after dosing (extended-release).
Metabolized primarily via UGT conjugation with minor CYP3A4 oxidation; elimination half-life ≈11 hours.
Approximately 45% excreted unchanged in urine (19% as glucuronide); exposure rises with declining renal function.

Dosing & administration

Label dose is 50 mg once daily with or without food; doses >100 mg/day add little efficacy and increase adverse effects.
Renal impairment: 50 mg every other day for CrCl 30–50 mL/min; 25 mg daily or 50 mg every other day for CrCl <30 mL/min; label recommends avoiding when CrCl <15 mL/min or on hemodialysis.
Tapering over ≥1–2 weeks can reduce discontinuation symptoms (dizziness, dysesthesias, irritability).
When discontinuation symptoms occur despite tapering, slower reductions over longer intervals are often better tolerated than larger dose drops.

Monitoring & labs

Blood pressure and heart rate at baseline and periodically, especially in patients with pre-existing hypertension.
Renal function for long-term therapy so dosing remains aligned with kidney function changes over time.
Discontinuation symptoms during missed doses or tapering; plan refill timing and taper steps are often planned in advance.
Mood elevation or agitation in bipolar-spectrum illness; coordinate prevention plans via the bipolar disorder hub.

Desvenlafaxine avoids CYP2D6-dependent activation, but blood pressure and taper planning remain the most clinically important follow-up items.

Adverse effects

FDA boxed warnings

Boxed warning: Antidepressants increase risk of suicidal thoughts and behaviors in young adults during initial treatment; monitoring is important.

Common side effects (≥10%)

Nausea: Most common adverse effect, typically transient.
Dizziness: Often linked to dose changes or discontinuation.
Insomnia or somnolence: Dose timing can be adjusted based on patient response.
Dry mouth/constipation: Hydration and fiber intake can help.
Hyperhidrosis: Hydration and clothing adjustments can help.

Other notable effects

Dose-related increases in blood pressure and heart rate—blood pressure and heart rate are typically checked at baseline and periodically, especially in hypertensive patients.
Hyponatremia/SIADH (particularly in older adults, diuretic users).
Rare hepatic injury; liver enzymes are checked if symptoms arise.
Withdrawal symptoms resembling venlafaxine (vertigo, “brain zaps”) if abruptly discontinued.
Emergent mania/hypomania in bipolar spectrum disorders—mood stabiliser coverage is typically maintained, and coordination with the bipolar disorder hub can help align relapse-prevention plans.

Interactions

Contraindicated with MAOIs or within 7 days of stopping desvenlafaxine (risk of serotonin syndrome).
Serotonergic agents (SSRIs, SNRIs, triptans, linezolid) increase serotonin syndrome risk—monitoring for agitation, clonus, and autonomic instability is important.
Additive bleeding risk with NSAIDs, antiplatelets, or anticoagulants.
Strong CYP3A4 inducers (carbamazepine, rifampin) may lower exposure; clinical response is monitored.

Other useful information

Tablet shell may appear in stool (ghost tablet); reassure patients that medication has been absorbed.
Renal function is typically checked at baseline and periodically for long-term therapy so dosing stays aligned with kidney function.
Counseling often covers recognizing serotonin syndrome and when to seek care for sustained hypertension, severe sweating, or emerging mania/hypomania; the bipolar disorder hub includes relapse-prevention resources.
Benefit typically builds over several weeks; early nausea or sleep disruption may improve with time, dose timing changes, or supportive care.

References

Related hubs:SMI toolkit·Support resources